Karyopharm Therapeutics Stock Price - KPTI

Best deals to access real time data!
Ultimate Trader (Monthly)
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Big Cap Pro
Monthly Subscription
for only
VAT not included
After Hours
Last Trade
Last $ 15.60 ◊ 0.00 (0.00%)
Company Name Stock Ticker Symbol Market Type
Karyopharm Therapeutics Inc KPTI NASDAQ Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  0.245 1.6% 15.60 15.78 15.26 15.42 15.355 19:51:29
Bid Price Ask Price Spread Spread % News
15.25 15.65 0.40 2.56% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
6,527 834,863 $ 15.51 $ 12,952,005 1,519,016 3.80 - 15.81
Last Trade Time Type Quantity Stock Price Currency
16:09:14 70 $ 15.60 USD

Karyopharm Therapeutics Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 979.52M 62.79M $ -178.41M -3.14 - 61.37M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% 4.00 2.30%

more financials information »

Karyopharm Therapeutics News

Loading Messages....

Latest KPTI Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical KPTI Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week14.2215.8114.2115.111,369,6331.389.7%
1 Month10.8515.8110.5313.251,452,6594.7543.78%
3 Months9.1115.818.0211.031,539,9586.4971.24%
6 Months4.6315.814.419.041,984,51910.97236.93%
1 Year10.1915.813.808.141,578,5915.4153.09%
3 Years9.9521.713.8010.08788,3985.6556.78%
5 Years39.82549.0053.8011.79604,267-24.23-60.83%

Karyopharm Therapeutics Description

Karyopharm Therapeutics Inc is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. The pipeline products of the company include Oral Selinexor, Oral Eltanexor, Oral Dual Inhibitor of PAK4 and NAMPT and Oral Verdinexor.

Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.